Equities

Mochida Pharmaceutical Co Ltd

Mochida Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,415.00
  • Today's Change50.00 / 1.49%
  • Shares traded20.30k
  • 1 Year change+7.22%
  • Beta0.3304
Data delayed at least 20 minutes, as of Jul 17 2024 05:56 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.

  • Revenue in JPY (TTM)102.89bn
  • Net income in JPY4.55bn
  • Incorporated1945
  • Employees1.52k
  • Location
    Mochida Pharmaceutical Co Ltd1-7, YotsuyaSHINJUKU-KU 160-8515JapanJPN
  • Phone+81 333587211
  • Fax+81 333587887
  • Websitehttps://www.mochida.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Katakura Industries Co., Ltd.39.83bn3.01bn71.17bn1.04k22.230.868312.091.7990.9090.901,203.272,327.460.28582.354.4938,300,000.002.292.352.993.3438.3037.758.018.322.58--0.109718.8116.62-2.048.0918.87-7.4610.76
ASKA Pharmaceutical Holdings Co Ltd62.84bn7.55bn73.99bn762.009.091.117.251.18266.48266.482,219.582,186.080.70661.694.0882,471,130.008.484.6311.085.8748.8046.9412.016.761.49--0.132814.863.946.1278.0334.04-37.8923.36
JCR Pharmaceuticals Co Ltd42.87bn5.51bn82.35bn934.0014.461.419.431.9243.9243.92342.31450.130.43490.58913.2945,900,430.005.628.668.4713.4672.9074.5112.9218.241.2227.690.293230.6024.8313.1146.008.1918.5421.67
Torii Pharmaceutical Co Ltd56.28bn5.29bn109.87bn583.0020.290.900719.131.95188.05188.052,002.444,235.560.42882.722.2596,531,740.004.036.524.447.3544.8349.559.4017.985.58--0.0024.1711.74-2.674.4428.76-20.3820.11
Kyorin Pharmaceutical Co Ltd119.53bn5.32bn111.00bn2.04k18.640.759111.550.928692.7092.702,082.822,276.510.67591.342.6158,536,730.003.013.053.903.7943.0147.114.454.761.45--0.138967.745.531.0212.68-4.987.41-7.06
Zeria Pharmaceutical Co Ltd75.73bn7.73bn114.21bn1.78k12.261.197.491.51175.39175.391,717.901,806.330.53041.483.9942,614,000.005.393.898.396.2873.2971.9310.167.570.794611.750.373535.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd102.89bn4.55bn126.27bn1.52k26.680.933617.171.23126.33126.332,868.833,609.590.64781.863.2867,598,550.002.864.373.445.3150.6152.474.426.713.31--0.002945.16-0.3641-1.26-31.61-11.6310.91-1.21
Nxera Pharma Co Ltd16.43bn-9.07bn151.04bn350.00--2.28--9.19-107.30-107.30194.96736.600.1309--5.7746,954,280.00-7.23-0.6588-7.78-0.703674.4489.83-55.20-4.464.03-10.910.5238---18.00---1,982.98------
Towa Pharmaceutical Co Ltd227.93bn16.17bn157.38bn4.59k9.300.96464.620.6905328.58328.584,630.883,167.260.56841.513.7049,680,470.004.034.215.035.6335.7039.237.107.231.46--0.564921.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd75.58bn11.16bn160.51bn1.78k13.200.65410.332.12246.57246.571,669.954,977.430.31351.562.9442,483,980.004.683.615.053.9049.4149.4714.9412.694.43--0.007834.8711.980.89196.0015.286.5810.40
Sumitomo Pharma Co Ltd314.56bn-314.97bn163.93bn4.98k--1.05--0.5212-792.79-792.79791.76392.820.3081.214.0563,164,260.00-30.84-5.07-54.58-7.7359.7669.99-100.12-12.280.2992--0.7332---43.38-7.29-322.71--4.02--
KAKEN PHARMACEUTICAL CO., LTD.72.04bn8.03bn186.42bn1.14k19.071.0717.302.59212.76212.761,909.113,796.040.42642.053.4063,474,890.004.756.835.407.8753.4954.7811.1414.484.72--0.026151.25-1.29-5.2147.52-14.700.36390.00
Data as of Jul 17 2024. Currency figures normalised to Mochida Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

8.71%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jul 2024832.31k2.22%
Nomura Asset Management Co., Ltd.as of 31 May 2024689.30k1.84%
Nikko Asset Management Co., Ltd.as of 05 Jul 2024328.70k0.88%
BlackRock Fund Advisorsas of 03 Jul 2024320.30k0.86%
Daiwa Asset Management Co. Ltd.as of 31 May 2024309.80k0.83%
Norges Bank Investment Managementas of 31 Dec 2023258.86k0.69%
Dimensional Fund Advisors LPas of 04 Jul 2024209.59k0.56%
Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Oct 2022147.10k0.39%
Charles Schwab Investment Management, Inc.as of 03 Jul 2024108.44k0.29%
BlackRock Advisors (UK) Ltd.as of 04 Jul 202457.50k0.15%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.